Cidara Therapeutics, Inc. (CDTX)

Overview

Cidara Therapeutics, Inc. is a pioneering biotechnology firm based in San Diego, California, focusing on the discovery, development, and commercialization of innovative long-acting anti-infectives for the treatment and prevention of various infectious diseases and in the field of oncology. Originally known as K2 Therapeutics, Inc., the company underwent a name change to Cidara Therapeutics, Inc. in July 2014, having been incorporated in 2012. Their work is primarily rooted in the United States, where they aim to address the critical need for new medications in the battle against infectious diseases associated with high mortality rates.

Products and Services

• Rezafungin Acetate

  A leading product candidate from Cidara Therapeutics, Rezafungin Acetate, represents a new molecule within the echinocandin class of antifungals. This novel therapeutic is in development for the treatment and prevention of invasive fungal infections, specifically candidemia and invasive candidiasis. These conditions are particularly notorious for their high mortality rates, underlining the importance of Rezafungin's role in healthcare.

• Cloudbreak Platform

  Cidara is advancing its proprietary Cloudbreak platform to develop a range of conjugates aimed at the prevention and treatment of influenza and other significant viral infections. These include but are not limited to:

  • Respiratory Syncytial Virus (RSV)
  • Human Immunodeficiency Virus (HIV)
  • The SARS-CoV-2 viruses responsible for COVID-19
  Each of these conjugates from the Cloudbreak platform is tailored to address the urgent need for effective treatments against these widespread and sometimes deadly viral infections, marking Cidara's commitment to innovation in the field of infectious disease management.